SAFC will provide protein isolation, extraction, and purification services to Curalogic in connection with the development of products focused on allergic rhinitis.
Curalogic seeks to develop pharmaceuticals that are just as effective as injection immunotherapy. Key products include a ragweed pollen extract that has just completed Phase II trials, a grass pollen extract and cat extract currently in Phase II, and a house dust mite extract that is in preclinical trials.
SAFC Pharma chemists working at the existing St. Louis protein purification and extraction facility will begin initial phases of the project. These phases explore development of grass and house dust mite compounds to determine a suitable process for producing sufficient quantities of cGMP material for future clinical trials and commercial launch of these products. Subsequent phases of the Curalogic project will be transferred into the SAFC plant after its scheduled completion in April 2007.